The Experts below are selected from a list of 60945 Experts worldwide ranked by ideXlab platform
Carl K. Chang - One of the best experts on this subject based on the ideXlab platform.
-
COMPSAC (Stephen S. Yau Academic Symposium) - Message from the Stephen S. Yau Academic Symposium Steering Committee Chair
2015 IEEE 39th Annual Computer Software and Applications Conference, 2015Co-Authors: Carl K. ChangAbstract:Presents the opening message from the Stephen S. Yau Academic Symposium Steering Committee chair.
-
SCC 2007 Technical Steering Committee
2007Co-Authors: Carl K. Chang, J.j.-p. Tsai, Hemant Jain, Zhiwei Xu, Ephraim Feig, Liang-jie ZhangAbstract:Sriram Anand, Accenture, India Kamal Bhattacharya, IBM T. J. Watson Research Center, USA Ganesh Bhutkar, Vishwakarma Institute of Technology, India Shuxing Cheng, Iowa State University, USA Trieu C. Chieu, IBM T. J. Watson Research Center, USA Wei Tan, IBM T. J. Watson Research Center, USA Karthikeyan Umapathy, Penn State University, USA Yi Zheng, University of Ontario Institute of Technology, Canada
-
technical Steering Committee
2007Co-Authors: Carl K. Chang, Liang-jie ZhangAbstract:Program Committee Sriram Anand, Accenture, India Sujoy Basu, HP Palo Alto Labs, USA Zhixiong Chen, Mercy College, USA Philippe Cudre-Mauroux, Massachusetts Institute of Technology, USA Suresh Damodaran, Massachusetts Institute of Technology, USA Nirmit Desai, IBM India Research Lab, India Reiner R. Dumke, University of Magdeburg, Germany Atilla Elci, Eatern Mediterranean University, Turkey Vadim Ermolayev, Zaporozhye National University, Ukraine Onyeka Ezenwoye, South Dakota State University, USA Vladimir Getov, University of Westminster, UK Satoshi Hada, IBM Tokyo Research Lab, Japan Ken Hopkinson, Air Force Institute of Technology, USA Sandeep M Karamongikar, InfoSys, India Konstantin Laufer, Loyola University Chicago, USA Gang Li, Chinese Academy of Sciences, China Dong Liu, Intel, USA Shiyong Lu, Wayne State University, USA Norbert Ritter, University of Hamburg, Germany Azzel Taleb-Bendiab, Liverpool John Moores University, UK Scott Tilley, Florida Institute of Technology, USA Vladimir Tosic, NICTA and University of New South Wales, Australia Hongji Yang, Montfort University, UK Jia Zhang, Northern Illinois University, USA Hong Zhu, Oxford Brookes University, UK Kezysztof Zielinski, University of Science and Technology, Poland
Fred R Hirsch - One of the best experts on this subject based on the ideXlab platform.
-
consensus report of a joint nci thoracic malignancies Steering Committee fda workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of master protocols in lung cancer
Journal of Thoracic Oncology, 2014Co-Authors: Shakun Malik, Richard Pazdur, Jeffrey S Abrams, Mark A Socinski, William T Sause, David H Harpole, John J Welch, Edward L Korn, Claudio Dansky Ullmann, Fred R HirschAbstract:On February 2, 2012, the National Cancer Institute (NCI) sponsored a 2-day workshop with the NCI Thoracic Malignancies Steering Committee and the Food and Drug Administration to bring together leading academicians, clinicians, industry and government representatives to identify challenges and potential solutions in the clinical development of novel targeted therapies for lung cancer. Measures of success are rapidly evolving from a scientific and regulatory perspective and the objectives of this workshop were to achieve initial consensus on a high priority biomarker-driven clinical trial designed to rapidly assess the activity of targeted agents in molecularly defined lung cancer subsets and to facilitate generation of data leading to approval of these new therapies. Additionally, the meeting focused on identification of the barriers to conduct such a trial and the development of strategies to overcome those barriers. The “Lung Master Protocols” recently launched by NCI were the direct outcome of this workshop.
Suzanne E Dahlberg - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy Steering Committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
current and future management of malignant mesothelioma a consensus report from the national cancer institute thoracic malignancy Steering Committee international association for the study of lung cancer and mesothelioma applied research foundation
Journal of Thoracic Oncology, 2018Co-Authors: Anne S Tsao, Wolf O Lindwasser, Alex A Adjei, Prasad S Adusumilli, Matthew L Beyers, Gideon M Blumenthal, Raphael Bueno, Bryan M Burt, Michele Carbone, Suzanne E DahlbergAbstract:On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
Warren P Mason - One of the best experts on this subject based on the ideXlab platform.
-
brain malignancy Steering Committee clinical trials planning workshop report from the targeted therapies working group
Neuro-oncology, 2015Co-Authors: Brian M Alexander, Evanthia Galanis, W Alfred K Yung, Karla V Ballman, James M Boyett, Timothy F Cloughesy, John Degroot, Jason T Huse, Bhupinder Mann, Warren P MasonAbstract:Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.
Anne S Tsao - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy Steering Committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
current and future management of malignant mesothelioma a consensus report from the national cancer institute thoracic malignancy Steering Committee international association for the study of lung cancer and mesothelioma applied research foundation
Journal of Thoracic Oncology, 2018Co-Authors: Anne S Tsao, Wolf O Lindwasser, Alex A Adjei, Prasad S Adusumilli, Matthew L Beyers, Gideon M Blumenthal, Raphael Bueno, Bryan M Burt, Michele Carbone, Suzanne E DahlbergAbstract:On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
